Based on the Dynavax Technologies Corporation stock forecast from 2 analysts, the average analyst target price for Dynavax Technologies Corporation is USD 26.00 over the next 12 months. Dynavax Technologies Corporation’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Dynavax Technologies Corporation is Neutral, which is based on 7 positive signals and 6 negative signals. At the last closing, Dynavax Technologies Corporation’s stock price was USD 12.45. Dynavax Technologies Corporation’s stock price has changed by -1.43% over the past week, -3.49% over the past month and -11.01% over the last year.
No recent analyst target price found for Dynavax Technologies Corporation
No recent average analyst rating found for Dynavax Technologies Corporation
Company Overview Dynavax Technologies Corporation
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California. Read Less
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in a...Read More
Frequently Asked Questions About Dynavax Technologies Corporation (DVAX) Stock
Based on ratings from 2 analysts Dynavax Technologies Corporation's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 3 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on DVAX's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for DVAX is USD 26.00 over the next 12 months. The maximum analyst target price is USD 31 while the minimum anlayst target price is USD 15.
DVAX stock's Price/Earning ratio is 86.67.
Our analysis grades DVAX stock's Price / Earning ratio at F. This means that DVAX stock's Price/Earning ratio is above 86% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this DVAX may be a overvalued for its sector.
The last closing price of DVAX's stock was USD 12.45.
The most recent market capitalization for DVAX is USD 1.71B.
Based on targets from 2 analysts, the average taret price for DVAX is projected at USD 26.00 over the next 12 months.
This means that DVAX's stock price may go up by +108.84% over the next 12 months.
We can't find any ETFs which contains Dynavax Technologies Corporation's stock.
As per our most recent records Dynavax Technologies Corporation has 408 Employees.
Dynavax Technologies Corporation's registered address is 2100 Powell Street, EmeryVille, CA, United States, 94608.
You can get more information about it from Dynavax Technologies Corporation's website at https://www.dynavax.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Dynavax Technologies Corporation (DVAX) Stock
Based on ratings from 2 analysts Dynavax Technologies Corporation's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 3 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on DVAX's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for DVAX is USD 26.00 over the next 12 months. The maximum analyst target price is USD 31 while the minimum anlayst target price is USD 15.
DVAX stock's Price/Earning ratio is 86.67.
Our analysis grades DVAX stock's Price / Earning ratio at F. This means that DVAX stock's Price/Earning ratio is above 86% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this DVAX may be a overvalued for its sector.
The last closing price of DVAX's stock was USD 12.45.
The most recent market capitalization for DVAX is USD 1.71B.
Based on targets from 2 analysts, the average taret price for DVAX is projected at USD 26.00 over the next 12 months.
This means that DVAX's stock price may go up by +108.84% over the next 12 months.
We can't find any ETFs which contains Dynavax Technologies Corporation's stock.
As per our most recent records Dynavax Technologies Corporation has 408 Employees.
Dynavax Technologies Corporation's registered address is 2100 Powell Street, EmeryVille, CA, United States, 94608.
You can get more information about it from Dynavax Technologies Corporation's website at https://www.dynavax.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for DVAX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
